{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T17:34:23Z","timestamp":1791999263512,"version":"4.4.0"},"reference-count":38,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T00:00:00Z","timestamp":1766102400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Hepatotoxicity is commonly observed in patients undergoing chemotherapy. However, the clinical features and outcomes of hepatotoxicity associated with anti-neoplastic agents remain unclear. In this study, we investigated the characteristics and risk factors of hepatotoxicity associatedwith anti-neoplastic agents.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a retrospective pharmacovigilance analysis using data acquired from the FDA Adverse Event Reporting System (FAERS) database (Q1\u20132004 to Q3 2024). Hepatotoxicity risk was assessed by disproportionality analysis, while LASSO and multivariate logistic regression were applied to control for potential confounders. Finally, we analyzed the time duration to the onset of hepatotoxicity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 56 anti-neoplastic agents exhibited positive signals for hepatotoxicity, involving 4,195 reports. Female patients (46.50%) were more frequently affected than males (26.70%), with a median age of 56 years. 627 patients (14.95%) experienced fatal or life-threatening outcomes. The top three drugs with the highest Reporting Odds Ratio (ROR) values were mercaptopurine (ROR = 26.57), pegaspargase (ROR = 13.67) and blinatumomab (ROR = 11.93). Most events occurred within the first month (44.18%) and the median TTO value in the Fatal group (22.5 days) was shorter than that in the non-fatal group (42 days) (p &amp;lt; 0.05). Furthermore, Weibull shape parameter (WSP) analysis indicated that 20 of the top 30 drugs were random failure models.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>This analysis profiles hepatotoxicity signals for anti-neoplastic agents but reveals a major methodological gap: without using a validated causality tool like the updated RUCAM, FAERS data cannot confirm druginduced liver injury (DILI). Future studies should integrate RUCAM to improvespecificity and clinical relevance.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2025.1665425","type":"journal-article","created":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T05:18:08Z","timestamp":1766121488000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Hepatotoxicity associated with anti-neoplastic agents: a pharmacovigilance analysis of the Food and Drug Administration Adverse Event Reporting System database"],"prefix":"10.3389","volume":"16","author":[{"given":"Lei","family":"Shi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Qu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,12,19]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-024-00778-4","article-title":"Conventional chemotherapy: millions of cures, unresolved therapeutic index","volume":"25","author":"Letai","year":"2025","journal-title":"Nat Rev Cancer"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2024.115361","article-title":"Navigating cancer therapy induced cardiotoxicity: From pathophysiology to treatment innovations","volume":"211","author":"Tetterton-Kellner","year":"2024","journal-title":"Adv Drug Delivery Rev"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2024-226350","article-title":"Association of methotrexate polyglutamates concentration with methotrexate efficacy and safety in patients with rheumatoid arthritis treated with predefined dose: results from the MIRACLE trial","volume":"84","author":"Tamai","year":"2025","journal-title":"Ann Rheum Dis"},{"key":"B5","doi-asserted-by":"publisher","first-page":"e70073","DOI":"10.1111\/liv.70073","article-title":"Ursodeoxycholic acid alone is effective and safe to treat cholestatic checkpoint inhibitor-induced liver injury","volume":"45","author":"Hountondji","year":"2025","journal-title":"Liver Int"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jep.2024.119293","article-title":"Pharmacodynamic material basis of licorice and mechanisms of modulating bile acid metabolism and gut microbiota in cisplatin-induced liver injury based on LC-MS and network pharmacology analysis","volume":"340","author":"Li","year":"2025","journal-title":"J Ethnopharmacol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"e2409107","DOI":"10.1002\/advs.202409107","article-title":"Geniposidic acid targeting FXR \"S332 and H447\" Mediated conformational change to upregulate CYPs and miR-19a-3p to ameliorate drug-induced liver injury","volume":"12","author":"Fan","year":"2025","journal-title":"Adv Sci (Weinh)"},{"key":"B8","doi-asserted-by":"publisher","first-page":"14","DOI":"10.3390\/ijms17010014","article-title":"RUCAM in drug and herb induced liver injury: the update","volume":"17","author":"Danan","year":"2016","journal-title":"Int J Mol Sci"},{"key":"B9","doi-asserted-by":"publisher","first-page":"564","DOI":"10.3390\/metabo12060564","article-title":"The potential role of metabolomics in drug-induced liver injury (DILI) assessment","volume":"12","author":"Moreno-Torres","year":"2022","journal-title":"Metabolites"},{"key":"B10","doi-asserted-by":"publisher","first-page":"803","DOI":"10.3390\/ijms18040803","article-title":"Drug induced liver injury: can biomarkers assist RUCAM in causality assessment","volume":"18","author":"Teschke","year":"2017","journal-title":"Int J Mol Sci"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-018-0654-2","article-title":"Drug-induced liver injury: why is the roussel uclaf causality assessment method (RUCAM) still used 25 years after its launch","volume":"41","author":"Danan","year":"2018","journal-title":"Drug Saf"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2015.05.003","article-title":"Risk of liver injury among methotrexate users: A meta-analysis of randomised controlled trials","volume":"45","author":"Conway","year":"2015","journal-title":"Semin Arthritis Rheum"},{"key":"B13","doi-asserted-by":"publisher","first-page":"e14281","DOI":"10.1111\/dth.14281","article-title":"Methotrexate vs secukinumab safety in psoriasis patients with metabolic syndrome","volume":"33","author":"Gisondi","year":"2020","journal-title":"Dermatol Ther"},{"key":"B14","doi-asserted-by":"publisher","first-page":"796","DOI":"10.7150\/ijms.6048","article-title":"Data mining of the public version of the FDA Adverse Event Reporting System","volume":"10","author":"Sakaeda","year":"2013","journal-title":"Int J Med Sci"},{"key":"B15","doi-asserted-by":"publisher","first-page":"7502","DOI":"10.1038\/s41467-022-35266-6","article-title":"Sex differences in allometry for phenotypic traits in mice indicate that females are not scaled males","volume":"13","author":"Wilson","year":"2022","journal-title":"Nat Commun"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.cld.2019.08.002","article-title":"Epidemiology, predisposing factors, and outcomes of drug-induced liver injury","volume":"24","author":"Bj\u00f6rnsson","year":"2020","journal-title":"Clin Liver Dis"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-024-10679-1","article-title":"Age-related differences in drug-induced liver injury: a retrospective single-center study from a large liver disease specialty hospital in China, 2002-2022","volume":"18","author":"Yu","year":"2024","journal-title":"Hepatol Int"},{"key":"B18","doi-asserted-by":"publisher","first-page":"390","DOI":"10.3390\/antiox10030390","article-title":"Oxidative stress in drug-induced liver injury (DILI): from mechanisms to biomarkers for use in clinical practice","volume":"10","author":"Villanueva-Paz","year":"2021","journal-title":"Antioxidants (Basel)"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.02555","article-title":"Severe hepatopathy in national wilms tumor studies 3-5: prevalence, clinical features, and outcomes after reintroduction of chemotherapy","volume":"41","author":"Oosterom","year":"2023","journal-title":"J Clin Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-019-09971-2","article-title":"Asparaginase-induced hepatotoxicity: rapid development of cholestasis and hepatic steatosis","volume":"13","author":"Kamal","year":"2019","journal-title":"Hepatol Int"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.19880","article-title":"Delaying pegaspargase during induction in adults with acute lymphoblastic leukaemia is associated with lower risk of high-grade hepatotoxicity without adversely impacting outcomes","volume":"206","author":"Tinajero","year":"2025","journal-title":"Br J Haematol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.4281","article-title":"Levocarnitine for pegaspargase-induced hepatotoxicity in older children and young adults with acute lymphoblastic leukemia","volume":"10","author":"Schulte","year":"2021","journal-title":"Cancer Med"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.50.2708","article-title":"Pharmacokinetics-based integration of multiple doses of intravenous pegaspargase in a pediatric regimen for adults with newly diagnosed acute lymphoblastic leukemia","volume":"32","author":"Douer","year":"2014","journal-title":"J Clin Oncol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.121.000828","article-title":"Novel bile acid-dependent mechanisms of hepatotoxicity associated with tyrosine kinase inhibitors","volume":"380","author":"Saran","year":"2022","journal-title":"J Pharmacol Exp Ther"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.41.0332","article-title":"Severe pazopanib-induced hepatotoxicity: clinical and histologic course in two patients","volume":"30","author":"Klempner","year":"2012","journal-title":"J Clin Oncol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.7150\/thno.99926","article-title":"Gut microbiota depletion and FXR inhibition exacerbates zonal hepatotoxicity of sunitinib","volume":"14","author":"Zhao","year":"2024","journal-title":"Theranostics"},{"key":"B27","doi-asserted-by":"publisher","first-page":"959","DOI":"10.3390\/ph18070959","article-title":"Beyond the basics: exploring pharmacokinetic interactions and safety in tyrosine-kinase inhibitor oral therapy for solid tumors","volume":"18","author":"Bud\u0103u","year":"2025","journal-title":"Pharm (Basel)"},{"key":"B28","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1097\/hep.0000000000000045","article-title":"Checkpoint inhibitor hepatotoxicity: pathogenesis and management","volume":"79","author":"Cunningham","year":"2024","journal-title":"Hepatology"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1002\/hep.31227","article-title":"Hepatotoxicity from immune checkpoint inhibitors: A systematic review and management recommendation","volume":"72","author":"Peeraphatdit","year":"2020","journal-title":"Hepatology"},{"key":"B30","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1136\/gut.18.3.196","article-title":"Chronic pancreatitis: a cause of cholestasis","volume":"18","author":"Scott","year":"1977","journal-title":"Gut"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.3390\/diagnostics15131588","article-title":"Drug-induced autoimmune hepatitis: robust causality assessment using two different validated and scoring diagnostic algorithms","volume":"15","author":"Teschke","year":"2025","journal-title":"Diagnostics (Basel)"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1097\/pas.0000000000000453","article-title":"Ipilimumab-associated hepatitis: clinicopathologic characterization in a series of 11 cases","volume":"39","author":"Johncilla","year":"2015","journal-title":"Am J Surg Pathol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1038\/s41419-024-06535-7","article-title":"Innate and adaptive immune cell interaction drives inflammasome activation and hepatocyte apoptosis in murine liver injury from immune checkpoint inhibitors","volume":"15","author":"Shojaie","year":"2024","journal-title":"Cell Death Dis"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1093\/omcr\/omx074","article-title":"Letrozole-induced hepatitis with autoimmune features: a rare adverse drug reaction with review of the relevant literature","volume":"2017","author":"Gharia","year":"2017","journal-title":"Oxford Med Case Rep"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2014-0021","article-title":"Bosutinib in combination with the aromatase inhibitor letrozole: a phase II trial in postmenopausal women evaluating first-line endocrine therapy in locally advanced or metastatic hormone receptor-positive\/HER2-negative breast cancer","volume":"19","author":"Moy","year":"2014","journal-title":"Oncologist"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2025.104720","article-title":"Pharmacogenomics in pediatric oncology patients with solid tumors related to chemotherapy-induced toxicity: A systematic review","volume":"211","author":"Hansson","year":"2025","journal-title":"Crit Rev In Oncology\/hematology"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.ecoenv.2024.117306","article-title":"STING signaling contributes to methotrexate-induced liver injury by regulating ferroptosis in mice","volume":"287","author":"Wang","year":"2024","journal-title":"Ecotoxicol Environ Saf"},{"key":"B38","doi-asserted-by":"publisher","first-page":"458","DOI":"10.3390\/diagnostics11030458","article-title":"Idiosyncratic drug-induced liver injury (DILI) and herb-induced liver injury (HILI): diagnostic algorithm based on the quantitative roussel uclaf causality assessment method (RUCAM)","volume":"11","author":"Teschke","year":"2021","journal-title":"Diagnostics (Basel)"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1665425\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T05:18:09Z","timestamp":1766121489000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1665425\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,19]]},"references-count":38,"alternative-id":["10.3389\/fimmu.2025.1665425"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1665425","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,19]]},"article-number":"1665425"}}